Background
Materials and methods
Clinical setting and the case
Antimicrobial agent | MIC (mg/L) | VITEK IIa | Micronauta |
---|---|---|---|
Amikacin | 4 | S | S |
Amoxicillin-clavulanate | 32 | R | – |
Ampicillin | 32 | R | R |
Cefazolin | 30 | R | R |
Cefepime | 4 | R | R |
Cefoxitin | 30 | – | R |
Cefotaxime | 2 | R | R |
Ceftazidime | 64 | R | R |
Ceftriaxone | 6 | R | – |
Chloramphenicol | 4 | – | S |
Ciprofloxacin | 0.5 | R | R |
Colistin | 1 | – | S |
Fosfomycin | < 32 | – | S |
Gentamicin | > 16 | R | – |
Imipenem | 4 | R | R |
Levofloxacin | 1 | – | R |
Meropenem | 8 | R | R |
Piperacillin | 16 | R | R |
Piperacillin-tazobactam | 64/4 | – | R |
Temocillin | < 32 | – | S |
Tigecycline | 0.25 | S | S |
Trimethoprim-sulfamethoxazole | 4/76 | R | R |
Genome sequencing, assembly, and analyses
Phylogenetic analysis and annotation
Results
Namea | MLST/pMLST | Size (Kb) | CDS/GC content | Resistance genes | Predicted phenotype |
---|---|---|---|---|---|
Chromosome | ST3510 | 5255.70 | 5816/57.35 | blaOKPB-3 | β-lactam |
oqxA | Fluoroquinolone | ||||
oqxB | Fluoroquinolone | ||||
pKPC-421 plasmid | IncX6 | 39.40 | 58/47.32 | blaKPC-2 | β-lactam |
pBK30683-like plasmid | IncFII | 136.16 | 199/55.48 | n/a | n/a |
pKq-NGSA-1 plasmid | IncFII(k) | 204.00 | 303/53.31 | aac(3)lla | Aminoglycoside |
aac(3″)lb | Aminoglycoside | ||||
aac(6′)lb-cr | Fluoroquinolone | ||||
aac(6)ld | β-lactam | ||||
blaOXA-1 | Phenicol | ||||
blaCTX-M-15 | |||||
blaTEM-1B | |||||
qnrB1 | Fluoroquinolone | ||||
catB3 Sul2 | Sulphonamide | ||||
tet(A) | Tetracycline | ||||
drA14 | Trimethoprim | ||||
pK245 plasmid | IncR | 134.81 | 188/53.68 | blaCTX-M-14b | β-lactam |